Innate Pharma S.A. Total Assets 2011-2026 | IPHA

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Innate Pharma S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
111 M	175 M	199 M	267 M	307 M	401 M	451 M	255 M	282 M	306 M	90.7 M	55.9 M	48.3 M	60.1 M

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
451 M	48.3 M	215 M

Quarterly Total Assets Innate Pharma S.A.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	267 M	-	266 M	-	307 M	-	-	-	401 M	-	-	-	451 M	-	-	-	255 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
451 M	255 M	325 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	16.1 M	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	514 M	$ 33.23	-4.03 %	$ 584 M	USA
Graybug Vision GRAY	13.6 M	-	-11.23 %	$ 9.65 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	1.08 B	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	1.36 B	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	105 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	690 M	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	936 M	$ 64.66	-1.37 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	1.83 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	3.11 B	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Certara CERT	1.56 B	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	35 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	473 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Capricor Therapeutics CAPR	58.7 M	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	1.1 B	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	149 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Corvus Pharmaceuticals CRVS	45.6 M	$ 17.75	-0.79 %	$ 852 M	USA
CTI BioPharma Corp. CTIC	126 M	-	-	$ 1.2 B	USA
CohBar CWBR	16.4 M	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	4.09 M	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	4.09 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	474 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	1.37 B	$ 20.02	-4.67 %	$ 3.29 B	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	31.7 M	$ 17.54	-3.36 %	$ 450 M	USA
Entasis Therapeutics Holdings ETTX	40.9 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	10.6 M	-	7.55 %	$ 38.1 M	USA